| |  Online-Ressource |
|---|
| Verfasst von: | Wischnewski, Sven [VerfasserIn]  |
|---|
| | Rausch, Hans-Werner [VerfasserIn] |
|---|
| | Ikenaga, Chiseko [VerfasserIn] |
|---|
| | Leipe, Jan [VerfasserIn] |
|---|
| | Lloyd, Thomas E. [VerfasserIn] |
|---|
| | Schirmer, Lucas [VerfasserIn] |
|---|
| Titel: | Emerging mechanisms and therapeutics in inflammatory muscle diseases |
|---|
| Verf.angabe: | Sven Wischnewski, Hans-Werner Rausch, Chiseko Ikenaga, Jan Leipe, Thomas E. Lloyd, and Lucas Schirmer |
|---|
| E-Jahr: | 2025 |
|---|
| Jahr: | March 2025 |
|---|
| Umfang: | 15 S. |
|---|
| Illustrationen: | Illustrationen |
|---|
| Fussnoten: | Online veröffetlicht: 11. Februar 2025, Artikelversion: 6. März 2025 ; Gesehen am 16.06.2025 |
|---|
| Titel Quelle: | Enthalten in: Trends in pharmacological sciences |
|---|
| Ort Quelle: | Amsterdam [u.a.] : Elsevier Science, 1979 |
|---|
| Jahr Quelle: | 2025 |
|---|
| Band/Heft Quelle: | 46(2025), 3, Seite 249-263 |
|---|
| ISSN Quelle: | 1873-3735 |
|---|
| Abstract: | Idiopathic inflammatory myopathies (IIMs), or myositis, are rare diseases marked by immune-driven muscle damage and complications like skin lesions and interstitial lung disease (ILD). Despite advances, challenges in diagnosis and treatment persist, particularly in inclusion body myositis (IBM), where no effective therapy exists. Recent breakthroughs, including transcriptomics and insights into antibody-mediated immunity and interferon (IFN) signaling, have clarified IIM pathophysiology and spurred the development of new therapies, such as chimeric antigen receptor (CAR) T cells and Janus kinase (JAK) inhibitors. We explore the latest findings on the mechanisms underlying adult-onset IIMs, emphasizing IBM pathobiology and its unique immune and degenerative pathways, such as a selective type 2 myofiber damage and severe cell stress. Finally, we highlight the recent advances in transcriptomics, single-cell analysis, and machine learning in transforming IIM research by improving diagnostic accuracy, uncovering therapeutic targets, and supporting the development of personalized treatment strategies. |
|---|
| DOI: | doi:10.1016/j.tips.2025.01.005 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
kostenfrei: Volltext: https://doi.org/10.1016/j.tips.2025.01.005 |
|---|
| | kostenfrei: Volltext: https://www.sciencedirect.com/science/article/pii/S0165614725000057 |
|---|
| | DOI: https://doi.org/10.1016/j.tips.2025.01.005 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | antisynthetase syndrome |
|---|
| | dermatomyositis |
|---|
| | idiopathic inflammatory myopathy |
|---|
| | immune-mediated necrotizing myopathy |
|---|
| | inclusion body myositis |
|---|
| | muscle inflammation |
|---|
| K10plus-PPN: | 1928250874 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Emerging mechanisms and therapeutics in inflammatory muscle diseases / Wischnewski, Sven [VerfasserIn]; March 2025 (Online-Ressource)
